left-arrow right-arrow pinterest facebook google_plus linkedin

NRG GY014

Status:

Recruiting | Phase II 

Official Title:

A phase II study of tazemetostat (EPZ-6438) (IND#138671) in recurrent or persistent endometrioid or clear cell carcinoma of the ovary, and recurrent or persistent endometrioid endometrial adenocarcinoma.

Study Purpose:

To find out if this approach is better or worse than the usual approach for your ovarian or endometrial cancer.  

Interventions:

  • Tazemetostat 800 mg (4 tablets by mouth two times a day) until disease progression or unacceptable toxicity.  
  • Patients must keep a pill diary.

Patients will be followed every 3 months for 2 years and then every 6 months for 3 years (5 years total).

Key Participation Requirements:

Gender:

Female

Age:

19 years and older

Diagnosis:

Pathologically proven diagnosis of recurrent or persistent ovarian endometrioid or clear cell carcinoma, OR recurrent or persistent endometrioid endometrial adenocarcinoma.

Eligibility:

Patients must have completed prior therapy anywhere from 14 days to 6 weeks before registration depending on which therapy regimen was assigned.

Patients must sign an approved informed consent and authorization permitting release of personal health information.

Methodist Health System Trial Code:

NRG GY014

For more information, visit the U.S. National Library of Medicine clinical trial database.

To learn more about this clinical trial please contact us today!